Delivery Order SPE2DB20D2104-SPE2DB25FMYWC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,385.39 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on June 17, 2025, with an ultimate completion date of June 18, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $48,927.46 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,291.93 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This competitively awarded, firm fixed-price contract was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting the competitive nature of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,506.04 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply). This firm fixed-price delivery order, awarded on July 2, 2025, with an ultimate completion date of July 3, 2025, represents a non-competitive, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $38,627.45 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count) on July 22, 2025, with completion expected by July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $7,448.66 delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Gemtesa 75 mg tablets (90 count). This is a firm fixed price, non-set-aside contract with a completion date of April 23, 2025, and performance to be executed in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $13,881.40 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90 count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $43,743.38. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $5,724.78. The award was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYWCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,914.29 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count packaging) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The Gemtesa order reflects the routine pharmaceutical procurement activities facilitated through this expansive contract platform, which encompasses specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 8/26/25 |